Published in Drug Week, August 7th, 2009
"This study tested the efficacy of the histone deacetylase inhibitor (HDACi), suberoylanilide hydroxamic acid (SAHA) in GH3, and MMQ pituitary adenoma cells. Clinically achievable concentrations of SAHA (500 nM-4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2009-08-07)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.